Pfizer Eyes Emergency Use Approval For Vaccine in November - COVID-19 Clinical Trial
Breaking News | COVID-19

Pfizer Eyes Emergency Use Approval For Vaccine in November

The American company told Reuters the data appeared inconsistent, the findings were premature and that other studies had validated the drug’s benefits. In a blow to one of the few drugs being used to treat people with COVID-19, the WHO said on Thursday its “Solidarity” trial had concluded that remdesivir appeared to have little or no effect on 28-day mortality or length of hospital stays among patients with the respiratory disease.

The antiviral medication was one of the drugs used to treat U.S. President Donald Trump’s coronavirus infection, and has been shown in previous studies to have cut time to recovery, though the European Union is investigating it for possible kidney injury. The WHO trial was conducted in 11,266 adult patients in more than 30 countries. The evidence was conclusive, the WHO said. Gilead said other trials of remdesivir, including with 1,062 patients that compared it with a placebo, showed the treatment cut COVID-19 recovery time.


Vast Majority of Air Cargo Companies are Unprepared to Transport Covid-19 Vaccines

As much of the world focuses on vaccine development to alleviate the pandemic, a new survey finds that just 28% of the air cargo companies that will play the highly crucial, behind-the-scenes role of transporting Covid-19 vaccines far and wide feel prepared for the job.

At the same time, 19% of these companies report that they feel “very unprepared.” And only 54% of airfreight providers currently have some of the necessary equipment for handling vaccines, according to the survey, which was conducted by the International Air Cargo Association and Pharma.Aero, an organization of air cargo carriers that specialize in shipping pharmaceuticals.

Share this:
Share on facebook
Facebook
Share on twitter
Twitter
Share on linkedin
LinkedIn
Share on reddit
Reddit
Share on email
Email
Scroll to Top

Your choice regarding cookies on this site

We use cookies to optimize site functionality and give you the best experience. Necessary cookies enable core functionality. The website cannot function properly without these cookies and can only be disabled by changing your browser preferences.

For more detailed information on the cookies we use, please check our Privacy Policy.

By continuing to access this website you are giving us consent to collect cookies.

Want to stay informed?

With an ever-changing situation like COVID-19, it’s important to stay as tuned in as possible. Submit your information below so we can send you periodic updates.